Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued on Monday,Benzinga reports.

A number of other equities research analysts also recently weighed in on AVXL. Jones Trading downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 1st. HC Wainwright restated a “buy” rating on shares of Anavex Life Sciences in a report on Friday, November 28th. Finally, Wall Street Zen lowered shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 23rd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Anavex Life Sciences currently has a consensus rating of “Hold” and a consensus target price of $44.00.

Anavex Life Sciences Trading Up 0.1%

Shares of Anavex Life Sciences stock traded up $0.01 during trading on Monday, reaching $3.90. The company’s stock had a trading volume of 204,552 shares, compared to its average volume of 1,453,949. The stock has a 50-day moving average price of $5.99 and a two-hundred day moving average price of $8.45. The stock has a market capitalization of $348.02 million, a P/E ratio of -7.21 and a beta of 1.15. Anavex Life Sciences has a one year low of $2.86 and a one year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Tuesday, November 25th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. During the same quarter last year, the firm posted ($0.14) earnings per share. As a group, sell-side analysts anticipate that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Anavex Life Sciences by 4.7% during the first quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company’s stock worth $42,061,000 after acquiring an additional 221,802 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Anavex Life Sciences by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company’s stock valued at $18,624,000 after purchasing an additional 54,985 shares during the last quarter. Two Sigma Investments LP increased its position in Anavex Life Sciences by 6.5% during the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock worth $9,229,000 after purchasing an additional 63,685 shares in the last quarter. Nwam LLC lifted its stake in Anavex Life Sciences by 2.4% in the 2nd quarter. Nwam LLC now owns 1,024,479 shares of the biotechnology company’s stock valued at $9,446,000 after purchasing an additional 24,128 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Anavex Life Sciences by 55.8% in the second quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company’s stock valued at $7,966,000 after buying an additional 309,605 shares in the last quarter. 31.55% of the stock is currently owned by institutional investors and hedge funds.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.